Despite prevailing financial market turbulence during the first quarter of 2015, it did not impede the ability of biotechs to raise capital. The period was characterized by a tsunami of cash flooding into their coffers. Both global public and private companies benefited from investors' seemingly insatiable appetite for their offerings.